Boehringer Begins Phase 3 Trial for Hep C Drug

E-mail Print PDF
RIDGEFIELD — Boehringer Ingelheim Pharmaceuticals has announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV).

The U.S. Food and Drug Administration (FDA) has granted “fast track designation for the development program for BI 201335. Fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The purpose is to get important new drugs to patients earlier.

"We are pleased to have begun enrolling patients at North American trial sites as we continue development of BI 201335," said Peter Piliero, MD, executive director of medical affairs for Boehringer Ingelheim. "We look forward to initiating additional trials later this year in more patient populations, including HCV-HIV coinfected patients, as we continue to advance our HCV portfolio."

There are currently three Phase 3 trials enrolling patients around the world that together seek to enroll approximately 1,875 patients. Two of the three trials have U.S. trial sites that together plan to enroll approximately 495 patients.
Should Connecticut Give Special Incentives to Individual Companies?

Google Search

If you aren't receiving your subscription, or you would like to cancel or change the address please contact us at:

This e-mail address is being protected from spambots. You need JavaScript enabled to view it

or fax 203-781-3482

Please provide you correct address and phone number.

To CANCEL your subscriptions please send an email with your current address for a single family home or name and address for a multi-family home, or business Indicate you want to cancel the subscription.

send the email to This e-mail address is being protected from spambots. You need JavaScript enabled to view it

To purchase a subscription, follow the link under About Us on the home page to a secure ecommerce site, managed by